Sotera Health beats estimates, extends revenue growth streak to 20 years
Sterilization services provider raises 2026 guidance on strong Sterigenics segment performance
Sotera Health delivered stronger-than-expected fourth quarter results, beating analyst estimates on adjusted earnings while extending its streak of annual revenue growth to two decades. The sterilization and laboratory testing services provider reported adjusted earnings per share of $0.26, topping the consensus estimate of $0.22 by 19.2 percent.
Full-year 2025 net revenues increased 5.7 percent to $1.164 billion, marking the 20th consecutive year of revenue growth for the Ohio-based company. Adjusted EBITDA rose 8.2 percent to $594 million, while adjusted EPS reached $0.86, an increase of $0.16 compared with the prior year.
Fourth quarter revenue of $303.4 million was essentially flat compared with analyst expectations, though the company highlighted robust performance from its Sterigenics segment, which grew 10.6 percent during the period. Sotera Health operates through three primary segments: Sterigenics provides sterilization services for medical devices and pharmaceutical products, Nelson Labs offers laboratory testing, and Sotera Health Advisory delivers consulting services.
The company improved its balance sheet during the year, reducing net leverage to 3.2 times from 3.7 times previously. This deleveraging position comes amid broader challenges in healthcare services, where many companies have faced pressure from rising interest costs and slowing procedure volumes in certain markets.
Looking ahead, Sotera Health provided 2026 guidance that exceeded analyst expectations. The company projected revenue of $1.23 billion to $1.25 billion, representing growth of 5.0 to 6.5 percent. Adjusted EBITDA is forecast between $632 million and $641 million, an increase of 5.5 to 7.0 percent. The midpoint of adjusted EPS guidance for 2026 sits at $0.97, surpassing analyst expectations by 3.3 percent.
Analysts have maintained largely positive ratings on the stock following the results. The median price target stands at $20.00, with eight analysts rating the shares a buy or strong buy versus two holds, according to recent data. Shares rose in after-hours trading following the earnings announcement.
The broader healthcare services sector has faced headwinds in recent quarters, including regulatory scrutiny of sterilization facilities following environmental concerns about ethylene oxide emissions at certain plants. Sotera Health has been working to address these issues through operational improvements and compliance investments.
Sotera Health serves customers across the medical device, pharmaceutical, and food industries in the Americas, Europe, and Asia. The company's services are considered essential to healthcare supply chains, as sterilization is required for most medical devices before they can be used in clinical settings. This defensive positioning has helped the company maintain consistent growth despite broader market volatility.
With a forward price-to-earnings ratio of approximately 20 times, compared with a trailing multiple above 87 times, the company appears to be trading at a valuation that reflects expectations for continued earnings acceleration. The stock has ranged between $9.53 and $19.85 over the past 52 weeks, closing at $17.49 in regular trading.